Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma
| Autor: | Sylvain Baruchel, Ira J. Dunkel, Douglas Strother, Mark Kowalski, Janet Gammon, Lia Gore, Kenneth J. Cohen, John F. Kuttesch, Stewart Goldman, David N. Korones, Jeffrey C. Allen, Amy Smith, Johannes E. A. Wolff, Ute Bartels, Michal Yalon, Eric Bouffet, Stephen Gilheeney, Roger J. Packer |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Pathology Adolescent medicine.medical_treatment Phases of clinical research Antibodies Monoclonal Humanized Cohort Studies Internal medicine Glioma medicine Brain Stem Neoplasms Humans Nimotuzumab Epidermal growth factor receptor Child Adverse effect Neoplasm Staging medicine.diagnostic_test biology business.industry Magnetic resonance imaging Prognosis medicine.disease Pons Survival Rate Radiation therapy Child Preschool Disease Progression biology.protein Female Neurology (clinical) Neoplasm Recurrence Local Safety business Pediatric Neuro-Oncology Follow-Up Studies medicine.drug |
| Zdroj: | Neuro-Oncology. 16:1554-1559 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/nou091 |
| Popis: | The prognosis of diffuse intrinsic pontine glioma (DIPG) remains poor, with no drug proven to be effective.Patients with clinically and radiologically confirmed, centrally reviewed DIPG, who had failed standard first-line therapy were eligible for this multicenter phase II trial. The anti-epidermal growth factor receptor (EGFR) antibody, nimotuzumab (150 mg/m(2)), was administered intravenously once weekly from weeks 1 to 7 and once every 2 weeks from weeks 8 to 18. Response evaluation was based on clinical and MRI assessments. Patients with partial response (PR) or stable disease (SD) were allowed to continue nimotuzumab.Forty-four patients received at least one dose of nimotuzumab (male/female, 20/24; median age, 6.0 years; range, 3.0-17.0 years). All had received prior radiotherapy. Treatment was well tolerated. Eighteen children experienced serious adverse events (SAEs). The majority of SAEs were associated with disease progression. Nineteen patients completed 8 weeks (W8) of treatment: There were 2 PRs, 6 SDs, and 11 progressions. Five patients completed 18 weeks (W18) of treatment: 1 of 2 patients with PR at W8 remained in PR at W18, and 3 of 6 children with SD at W8 maintained SD at W18. Time to progression following initiation of nimotuzumab for the 4 patients with SD or better at W18 was 119, 157, 182 and 335 days, respectively. Median survival time was 3.2 months. Two patients lived 663 and 481 days from the start of nimotuzumab.Modest activity of nimotuzumab in DIPG, which has been shown previously, was confirmed: A small subset of DIPG patients appeared to benefit from anti-EGFR antibody treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|